StockVS

Akso Health Group (AHG) Stock Analysis

Healthcare

Akso Health Group

$1.60

+$0.07 (+4.58%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

Akso Health Group operates a specialized social e-commerce mobile platform within the People's Republic of China, facilitating the distribution of food and beverage products, wine, cosmetic products, fashion and apparel, and entertainment items through its Xiaobai Maimai App. This business model places the company firmly within the Healthcare sector, specifically under the industry classification of Medical Distribution, where it manages the logistics and supply chain for medical and wellness-related goods. The enterprise maintains a market capitalization of $2.02B while employing a workforce of 27 individuals, generating total annual revenue of $14.84M based on trailing twelve-month data. The combination of a $2.02B market cap with revenue of only $14.84M indicates that the company's valuation is driven largely by market sentiment or speculative factors rather than current revenue generation scale, creating a significant disparity between its asset value and operational output. Furthermore, the extremely low employee count of 27 suggests a highly automated or capital-intensive operational model, or potentially significant off-balance-sheet employment structures, which contrasts sharply with the massive valuation multiple assigned to its sales figures.

Financial Health

The company reports a trailing twelve-month revenue of $14.84M, yet this figure masks a severe profitability crisis as the net income stands at -$135,666,432, revealing a cost structure where expenses vastly exceed all income. Additionally, the EBITDA is reported at -$1,462,343, further confirming that the business operations are not generating sufficient cash from core activities before interest and taxes. The free cash flow is a substantial -$169,332,416, which indicates a complete lack of financial flexibility, as the company is burning through cash reserves at a rapid pace without organic cash generation. Analyzing the margins, the gross margin is a negligible 1.0%, suggesting that the cost of goods sold consumes nearly all of the revenue before operating expenses are even considered. The operating margin is -20.5% and the profit margin is 0.0%, illustrating that for every dollar of revenue, the company loses twenty cents to operating costs and fails to retain any profit for shareholders. On the balance sheet, the company holds $11.13M in cash against total debt of $2.06M, which appears conservative on the surface, yet the debt-to-equity ratio of 1.04 suggests a level of leverage that is difficult to manage given the negative cash flows. The current ratio is 1.53, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though this liquidity is being eroded by the heavy free cash flow burn. Finally, the return on equity is -68.3% and the return on assets is -1.4%, metrics that reveal management is currently ineffective at generating value from either shareholder equity or the total asset base.

Valuation Assessment

The trailing P/E ratio is listed as N/A and the forward P/E is also N/A, implying that the company has no earnings in the traditional sense and that future earnings expectations are currently undefined or non-existent in the eyes of analysts. Without a valid P/E ratio, the market relies on alternative valuation metrics, where the price-to-book ratio is 10.22, indicating that the stock is trading at a significant premium of over ten times its book value despite the company's negative earnings and cash flow. The price-to-sales ratio is 136.22, a metric that suggests the market is willing to pay 136 dollars for every dollar of sales, which is historically extreme for a mature distributor and highlights a complete disconnect between sales performance and stock price. The EV/EBITDA is -4141.58, a negative multiple that further underscores the company's inability to service debt or generate operational profit, rendering traditional enterprise value multiples meaningless in this context. Regarding price volatility, the stock has a 52-week high of $2.50 and a 52-week low of $0.83, meaning the current price sits somewhere within this range but with a beta of -0.66. This negative beta value indicates that the stock's price movement is inversely correlated to the broader market, moving in the opposite direction when the market rises or falls, which presents a unique but risky volatility profile for investors.

Growth & Income

The revenue growth year-over-year is 0.9%, while the earnings growth is N/A due to the persistent net losses, meaning that the company is barely expanding its sales top-line while its profitability remains deeply entrenched in the negative. Because the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which indicates that the firm reinvests its minimal remaining capital or retains its cash reserves rather than distributing income to shareholders. The absence of dividends combined with the massive free cash flow burn suggests that the company is prioritizing survival over shareholder returns, a strategy often adopted by firms in distress that are attempting to rebuild their balance sheets. Overall, the growth and income profile is characterized by stagnant revenue expansion and a total absence of income generation, leaving the company reliant on its existing cash hoard of $11.13M to fund operations indefinitely without external financing.

Peer Comparison

Akso Health Group (AHG) operates in the Medical Distribution industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Akso Health Group AHG $1.37B N/A
McKesson Corporation MCK $90.68B 19.6
Cencora, Inc. COR $52.68B 20.8
Cardinal Health, Inc. CAH $46.93B 30.6

The Medical Distribution industry average P/E ratio is 23.3x. Akso Health Group trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Akso Health Group

Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People's Republic of China. It operates Xiaobai Maimai App, a social e-commerce mobile platform that offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. The company also sells medical devices, such as defibrillators and anesthesia laryngoscopes. In addition, it provides health treatment, consultancy support, and marketing promotion services, as well as technological promotion services and import and export. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Qingdao, China.

Visit website →

Key Statistics

Market Cap
$1.37B
P/E Ratio
N/A
52-Week High
$2.50
52-Week Low
$1.07
Avg Volume
143.73K
Beta
-0.90

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NASDAQ
Country
China
Employees
27